Terms: = Lung cancer AND TRIM24, O15164, 8805, ENSG00000122779, TIF1ALPHA, TF1A, TIF1A, hTIF1, Tif1a, TIF1, RNF82, PTC6
47 results:
1. Clinical, histologic and prognostic features of clinically amyopathic dermatomyositis.
Fornaro M; Girolamo F; Giannini M; Coladonato L; Capuano A; Capodiferro M; D'Abbicco D; Ruggieri M; Mastrapasqua M; Iannone F
Clin Exp Rheumatol; 2024 Feb; 42(2):288-294. PubMed ID: 38488091
[TBL] [Abstract] [Full Text] [Related]
2. Synthesis, Computational, and Anticancer In Vitro Investigations of Aminobenzylnaphthols Derived from 2-Naphtol, Benzaldehydes, and α-Aminoacids via the Betti Reaction.
Kciuk M; Malinowska M; Gielecińska A; Sundaraj R; Mujwar S; Zawisza A; Kontek R
Molecules; 2023 Oct; 28(20):. PubMed ID: 37894709
[TBL] [Abstract] [Full Text] [Related]
3. Clinical features of dermatomyositis patients with anti-tif1 antibodies: A case based comprehensive review.
Kilinc OC; Ugurlu S
Autoimmun Rev; 2023 Dec; 22(12):103464. PubMed ID: 37863375
[TBL] [Abstract] [Full Text] [Related]
4. [Risk factors analysis and prediction model establishment of malignant tumor in patients with polymyositis/dermatomyositis].
Wang YF; Li HX; Feng Y; Zhang Y; Wu ZB
Zhonghua Yi Xue Za Zhi; 2023 Jul; 103(25):1903-1910. PubMed ID: 37402671
[No Abstract] [Full Text] [Related]
5. Clinical features and risk factors of lung cancer in elderly patients with dermatomyositis.
Zhou B; Li S; Xie X; Xu S; Li F; Long L
Thorac Cancer; 2023 May; 14(13):1171-1178. PubMed ID: 37042120
[TBL] [Abstract] [Full Text] [Related]
6. Characteristics of anti-transcriptional intermediary factor 1 gamma autoantibody-positive dermatomyositis patients in Singapore.
Chua CG; Low JZ; Lim WY; Manghani M
Ann Acad Med Singap; 2022 Dec; 51(12):755-765. PubMed ID: 36592144
[TBL] [Abstract] [Full Text] [Related]
7. Immune checkpoint inhibitor therapy in a patient with small cell lung cancer and anti-transcriptional intermediary factor 1-γ antibody-positive dermatomyositis: A case report.
Kim Y; Park D; Choi SY; Chung C
Thorac Cancer; 2022 Oct; 13(19):2808-2811. PubMed ID: 35982637
[TBL] [Abstract] [Full Text] [Related]
8. The associations between myositis autoantibodies and clinical presentations in dermatomyositis.
Su HJ; Chung WH; Lin CY
Australas J Dermatol; 2022 Nov; 63(4):479-487. PubMed ID: 35917132
[TBL] [Abstract] [Full Text] [Related]
9. Myositis-specific autoantibodies and their clinical associations in idiopathic inflammatory myopathies: results from a cohort from China.
Wen L; Chen X; Cheng Q; Nie L; Xu J; Yan T; Zhang X; Yang H; Sun W; Liu L; Xue J; Du Y
Clin Rheumatol; 2022 Nov; 41(11):3419-3427. PubMed ID: 35859245
[TBL] [Abstract] [Full Text] [Related]
10. cancer associated autoantibodies in idiopathic inflammatory myopathies: A retrospective cohort from a single center in China.
Zhao Y; Su H; Yin X; Hou H; Wang Y; Xu Y; Li X; Zhang N; Sun W; Wei W
Med Clin (Barc); 2023 Jan; 160(1):10-16. PubMed ID: 35842306
[TBL] [Abstract] [Full Text] [Related]
11. Development of dermatomyositis after anti-transcriptional intermediary factor 1-γ antibody seroconversion during treatment for small cell lung cancer.
Sato Y; Tanino Y; Nikaido T; Togawa R; Kawamata T; Watanabe N; Sato R; Yamada R; Onuma T; Tomita H; Saito M; Rikimaru M; Morimoto J; Suzuki Y; Minemura H; Saito J; Kanazawa K; Yamada S; Hashimoto Y; Shibata Y
BMC Pulm Med; 2022 May; 22(1):191. PubMed ID: 35549684
[TBL] [Abstract] [Full Text] [Related]
12. Clinical significance of anti-transcriptional intermediary factor 1-γ antibody in patients with dermatomyositis: a monocentric cross-sectional study.
Yang H; Yan T; Zhang X; Sun W; Liu L; Du Y; Xue J
Clin Rheumatol; 2022 Aug; 41(8):2439-2448. PubMed ID: 35422109
[TBL] [Abstract] [Full Text] [Related]
13. High expression of trim24 predicts worse prognosis and promotes proliferation and metastasis of epithelial ovarian cancer.
Zhang L; Chen H; Ding B; Jiang W
J Ovarian Res; 2022 Feb; 15(1):19. PubMed ID: 35105347
[TBL] [Abstract] [Full Text] [Related]
14. Smoking-associated upregulation of CBX3 suppresses ARHGAP24 expression to activate Rac1 signaling and promote tumor progression in lung adenocarcinoma.
Jin X; Zhang B; Zhang H; Yu H
Oncogene; 2022 Jan; 41(4):538-549. PubMed ID: 34785774
[TBL] [Abstract] [Full Text] [Related]
15. Anti-tif1 gamma-positive IPAF patient developed stage IVB lung squamous carcinoma in 1 year: a case report.
Xie JJ; Li B; Xu R; Du XZ; He JZ
BMC Pulm Med; 2021 Jun; 21(1):204. PubMed ID: 34193090
[TBL] [Abstract] [Full Text] [Related]
16. Myositis-specific antibodies and clinical characteristics in patients with autoimmune inflammatory myopathies: reported by the Argentine Registry of Inflammatory Myopathies of the Argentine Society of Rheumatology.
Gómez GN; Pérez N; Braillard Poccard A; Gómez RA; Costi AC; García MA; Viola M; Benitez A; Aciar MM; Crespo Espíndola M; Yucra D; Cosatti MA; Pisoni C; Capelusnik D; Lojo MN; Barrios BI; Rivero M; Kisluk B; Granel A
Clin Rheumatol; 2021 Nov; 40(11):4473-4483. PubMed ID: 34159491
[TBL] [Abstract] [Full Text] [Related]
17. [Comparison of clinical and immunological features between clinically amyopathic dermatomyositis and typical dermatomyositis].
Gan YZ; Li YH; Zhang LH; Ma L; He WW; Jin YB; An Y; Li ZG; Ye H
Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Dec; 52(6):1001-1008. PubMed ID: 33331305
[TBL] [Abstract] [Full Text] [Related]
18. Long non‑coding RNA ZFPM2‑AS1 promotes colorectal cancer progression by sponging miR‑137 to regulate trim24.
Xiao M; Liang Z; Yin Z
Mol Med Rep; 2021 Feb; 23(2):. PubMed ID: 33300060
[TBL] [Abstract] [Full Text] [Related]
19. [Dermatomyositis with squamous cell carcinoma of the lungs secondary to nivolumab treatment: a case report].
Miyashita K; Kajikawa H; Utsunomiya T; Hosaka M; Naito Y; Tomimoto H
Rinsho Shinkeigaku; 2020 Nov; 60(11):768-772. PubMed ID: 33115992
[TBL] [Abstract] [Full Text] [Related]
20. Paraneoplastic Dermatomyositis in a Patient with Metastatic Gastric Carcinoma.
Pozharashka J; Dourmishev L; Rusinova D; Balabanova M; Miteva L
Acta Dermatovenerol Croat; 2020 Aug; 28(2):120-122. PubMed ID: 32876041
[TBL] [Abstract] [Full Text] [Related]
[Next]